Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration's Evaluation

Assessing a drug for an eradicated human disease: US Food and Drug Administration review of tecovirimat for the treatment of smallpox

(2019) Kirk M Chan-Tack et al.   LANCET INFECTIOUS DISEASES

The development and approval of tecoviromat (TPOXX®), the first antiviral against smallpox

(2019) Michael Merchlinsky et al.   ANTIVIRAL RESEARCH

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation

(2018) Francisco M. Marty et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: A model of smallpox disease

(2015) Lawrence C. Trost et al.   ANTIVIRAL RESEARCH

CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation

(2013) Francisco M. Marty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox – An animal model of smallpox

(2012) Scott Parker et al.   ANTIVIRAL RESEARCH

Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: Pathogenesis, prophylaxis, and antiviral therapy

(2010) Nanhai Chen et al.   VIROLOGY

Efficacy of therapeutic intervention with an oral ether–lipid analogue of cidofovir (CMX001) in a lethal mousepox model

(2007) Scott Parker et al.   ANTIVIRAL RESEARCH